147 related articles for article (PubMed ID: 19887957)
1. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis.
Chan CC; Reid CM; Aw TJ; Liew D; Haas SJ; Krum H
J Hypertens; 2009 Dec; 27(12):2332-41. PubMed ID: 19887957
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.
Aw TJ; Haas SJ; Liew D; Krum H
Arch Intern Med; 2005 Mar; 165(5):490-6. PubMed ID: 15710786
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
6. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
7. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
8. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
[TBL] [Abstract][Full Text] [Related]
9. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
11. COX-2 selective inhibitors in the treatment of osteoarthritis.
Laine L; White WB; Rostom A; Hochberg M
Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP; Gertler R; Fricker R
Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
15. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
17. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials.
Chen LC; Ashcroft DM
J Clin Pharm Ther; 2006 Dec; 31(6):565-76. PubMed ID: 17176361
[TBL] [Abstract][Full Text] [Related]
18. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
19. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.
Yang M; Wang HT; Zhao M; Meng WB; Ou JQ; He JH; Zou B; Lei PG
Medicine (Baltimore); 2015 Oct; 94(40):e1592. PubMed ID: 26448006
[TBL] [Abstract][Full Text] [Related]
20. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
Hermann M; Ruschitzka F
Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]